Search Results

You searched for : Boehringeringelheim

	Boehringer Ingelheim's Investigational Treatment for Schizophrenia receives FDA Breakthrough Therapy Designation The company also announced the planned initiation of the innovative CONNEX Phase III clinical trial program assessing the safety and efficacy of BI 425809 ... May 27
	New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1 New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1... Nov 07
	Alembic Pharma receives USFDA tentative approval for Empagliflozin and Linagliptin tablets Empagliflozin and Linagliptin tablets, have an estimated market size of US$ 244 million for twelve months ending June 2020... Aug 27
	Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio Boehringer Ingelheim Acquires Northern Biologicsâ€™ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio ... May 16
	Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (... Mar 03
	Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies ... Sep 21
6 Matching result(s) found!

-Advertisements-

Trending Now
	Dish TV Revolutionizes Entertainment with ‘Dish TV Smart+’ Services, Offering TV and OTT on Any Screen, AnywhereApril 26, 2024
	Arohan Financial Services Recognized Among India's Best Workplaces in BFSI 2024April 26, 2024
	Why Podcasts Are the Next Big Thing in Healthcare Advertising in IndiaApril 26, 2024
	Challenges of Child Growth at High Altitudes: New Study Reveals ImpactApril 26, 2024
	Staying Cool in India's Scorching Heat: Heatwave Safety TipsApril 26, 2024
	The Dark Side of Neotame (Artificial Sweetener): New Research Raises Concerns about Gut HealthApril 26, 2024
	Sightsavers India Fellowship Program Invites Applications for Promising OphthalmologistsApril 25, 2024
	Transforming Brain Healthcare: India's Visionary Task Force for Neurological DisordersApril 25, 2024
	The Battle Against Malaria: Rising Trends and Vaccine InnovationsApril 25, 2024
	Talc and Asbestos Controversy: Inside Johnson & Johnson's Courtroom StruggleApril 25, 2024
	The Hidden Struggles of Parenthood: Addressing Isolation, Loneliness, and BurnoutApril 25, 2024
	FDA Confirms Bird Flu Virus Remnants in Pasteurized Milk: Safety and Regulatory InsightsApril 24, 2024
	Sarvodaya Hospital Redefines Total Knee Replacement Surgery with Augmented Reality April 23, 2024
	Fateh Education announces partnership to expand educational opportunities for Indian studentsApril 23, 2024
	10 Strategies to counter disinformation for the healthcare digital ecosystemApril 23, 2024
	Is Selling Over-the-Counter (OTC) Drugs in General Stores A Step Towards Affordable Healthcare in IndiaApril 23, 2024
	Student Health Crisis: Food Poisoning Incident Strikes Pune Coaching CentreApril 23, 2024
	The Impact of Diabetes on Kidney Health: Diabetic Nephropathy ExplainedApril 23, 2024
	Toddler Hospitalized After Consuming Expired Chocolates: Health Concerns RaisedApril 23, 2024
	After months of diagnostic delay, a migrant worker could access TB services only when a community health worker met himApril 22, 2024

Search Results

Boehringer Ingelheim's Investigational Treatment for Schizophrenia receives FDA Breakthrough Therapy Designation

New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1

Alembic Pharma receives USFDA tentative approval for Empagliflozin and Linagliptin tablets

Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Trending Now